rVSV-ZEBOV (Ervebo) Vaccine: Comprehensive Overview (en.wikipedia.org)

• First licensed Ebola vaccine; 100% efficacy in Guinea ring trial (2015).
• Approved by FDA and EMA in 2019; used extensively in DRC outbreaks.
• Live-attenuated rVSV vector expressing Zaire ebolavirus GP.
• Requires ultra-cold chain storage; single-dose regimen.

"The rVSV-ZEBOV vaccine, marketed as Ervebo, is a live-attenuated vaccine for Ebola virus disease (EVD) caused by Zaire ebolavirus. Developed by Merck, it received FDA and EMA approval in 2019 after a 2015 ring vaccination trial in Guinea demonstrated 100% efficacy. It is administered as a single dose and has been critical in outbreak response, particularly in the DRC. The vaccine induces neutralizing antibodies against the Ebola glycoprotein and has a safety profile of mostly mild to moderate adverse events. It remains a cornerstone of the WHO's Ebola response strategy."